⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161800 | 0.73 | — | — | |
| SCHEMBL11135783 | 0.73 | — | — | |
| SCHEMBL4430848 | 0.69 | — | — | |
| SCHEMBL9424952 | 0.69 | — | — | |
| SCHEMBL3973875 | 0.67 | — | — | |
| SCHEMBL7317046 | 0.66 | — | — | |
| SCHEMBL60694 | 0.65 | — | — | |
| SCHEMBL15161 | 0.65 | — | — | |
| SCHEMBL186450 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL473386 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359534-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE | Dyne Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11891605-B2 | Reducing intron retention | UNIVERSITY OF SOUTHAMPTON (GB) | 2024-02-06 | — | — | US | claimed |
| WO-2024011135-A2 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| US-20230416756-A1 | MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION | UNIVERSITY OF SOUTHAMPTON (GB) | 2023-12-28 | — | — | US | claimed |
| EP-4271478-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Dyne Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| US-11702660-B2 | Modulation of gene expression and screening for deregulated protein expression | UNIVERSITY OF SOUTHAMPTON (GB) | 2023-07-18 | — | — | US | claimed |
| US-20230183693-A1 | REDUCING INTRON RETENTION | UNIVERSITY OF SOUTHAMPTON (GB) | 2023-06-15 | — | — | US | claimed |
| EP-4146233-A2 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING CD70 SPECIFIC FUSION PROTEINS | TCR2 Therapeutics Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20230072532-A1 | COMPOSITIONS COMPRISING MODIFIED CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-03-09 | — | — | US | claimed |
| WO-2022271549-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE | DYNE THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | claimed |
| US-20160244762-A1 | REDUCING INTRON RETENTION | UNIVERSITY OF SOUTHAMPTON (GB) | 2016-08-25 | — | — | US | claimed |
| US-20160017322-A1 | REDUCING INTRON RETENTION | UNIVERSITY OF SOUTHAMPTON (GB) | 2016-01-21 | — | — | US | claimed |
| JP-2009502138-A | — | — | 2009-01-29 | — | — | JP | claimed |
| EP-1563070-A4 | 2'-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACEUTICALS INC (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1909850-A2 | RNAI MODULATION OF THE RHO-A GENE AND USES THEREOF | Alnylam Pharmaceuticals Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007014077-A2 | RNAI MODULATION OF THE RHO-A GENE AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | claimed |
| EP-1563070-A2 | 2'-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | Isis Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040171033-A1 | 2'-substituted oligomeric compounds and compositions for use in gene modulations | ISIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004044140-A2 | 2’-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACETICALS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-5731128-A | ELASTICITY, HARDNESS, ELONGATION; WATER DEVELOPABILITY | NIPPON PAINT CO., LTD. (JP) | 1998-03-24 | — | — | US | claimed |